Cargando…
射频透热联合化疗治疗肺癌恶性心包积液的近期疗效
BACKGROUND AND OBJECTIVE: Malignant pericardial effusion is one of the serious complications of lung cancer and lack effective treatment methods. The aim of this study is to evaluate the efficacy and safety of radiofrequency hyperthermia combined with chemotherapy for patients with malignant pericar...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
中国肺癌杂志编辑部
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000271/ https://www.ncbi.nlm.nih.gov/pubmed/21762629 http://dx.doi.org/10.3779/j.issn.1009-3419.2011.07.06 |
_version_ | 1783331664875749376 |
---|---|
collection | PubMed |
description | BACKGROUND AND OBJECTIVE: Malignant pericardial effusion is one of the serious complications of lung cancer and lack effective treatment methods. The aim of this study is to evaluate the efficacy and safety of radiofrequency hyperthermia combined with chemotherapy for patients with malignant pericardial effusion caused by lung cancer. METHODS: Fify-five patients with malignant pericardial effusion caused by lung cancer were divided into hyperthermia combined with chemotherapy group (combined therapy group) and chemotherapy group. The combined therapy group was treated with radiofrequency hyperthermia afer the pericardiocentesis and intracavitary injection (cisplatin 20 mg and dexamethasone 5 mg), when patients' general state of health improved, systemic chemotherapy was performed. The chemotherapy group was treated only with intracavitary injection and systemic chemotherapy. Intracavitary chemotherapy was performed for 1-6 times (average 3 times). Hyperthermia was performed twice per week with an average of 6 times following intracavitary and systemic chemotherapy. The temperature of intracavitary was 40.5 oC-41.5 oC for 60 min during the hyperthermia periods. Systemic chemotherapy consists of cisplatin (75 mg/m(2)) and vinorelbine (50 mg/m(2)). RESULTS: The complete remission rate (CR) of malignant pericardial effusion was 54.3% and the response rate (RR) was 91.4% in the combined therapy group, while the rates of CR and RR of chemotherapy group were 25.0% and 70.0%, and the differences of CR and RR between the two groups were signifcant (P < 0.05). Afer treatment, the quality of life improved signifcantly in both groups, but the combined therapy group had a higher KPS score than in the chemotherapy group (P < 0.05). The adverse events associated with the chemotherapy included gastrointestinal toxicity and myelosup-pression, and there were no signifcant differences between the two groups. The main side effects associated with radiofrequency hyperthermia included local skin ache (8.6%) and induration of subcutaneous fat (5.7%). CONCLUSION: Radiofrequency hyperthermia combined with chemotherapy is effective in treatment of malignant pericardial effusion and can signifcantly improve the quality of life of patients without increasing the toxicity of chemotherapy, and side effects could be tolerable. |
format | Online Article Text |
id | pubmed-6000271 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | 中国肺癌杂志编辑部 |
record_format | MEDLINE/PubMed |
spelling | pubmed-60002712018-07-06 射频透热联合化疗治疗肺癌恶性心包积液的近期疗效 Zhongguo Fei Ai Za Zhi 临床经验 BACKGROUND AND OBJECTIVE: Malignant pericardial effusion is one of the serious complications of lung cancer and lack effective treatment methods. The aim of this study is to evaluate the efficacy and safety of radiofrequency hyperthermia combined with chemotherapy for patients with malignant pericardial effusion caused by lung cancer. METHODS: Fify-five patients with malignant pericardial effusion caused by lung cancer were divided into hyperthermia combined with chemotherapy group (combined therapy group) and chemotherapy group. The combined therapy group was treated with radiofrequency hyperthermia afer the pericardiocentesis and intracavitary injection (cisplatin 20 mg and dexamethasone 5 mg), when patients' general state of health improved, systemic chemotherapy was performed. The chemotherapy group was treated only with intracavitary injection and systemic chemotherapy. Intracavitary chemotherapy was performed for 1-6 times (average 3 times). Hyperthermia was performed twice per week with an average of 6 times following intracavitary and systemic chemotherapy. The temperature of intracavitary was 40.5 oC-41.5 oC for 60 min during the hyperthermia periods. Systemic chemotherapy consists of cisplatin (75 mg/m(2)) and vinorelbine (50 mg/m(2)). RESULTS: The complete remission rate (CR) of malignant pericardial effusion was 54.3% and the response rate (RR) was 91.4% in the combined therapy group, while the rates of CR and RR of chemotherapy group were 25.0% and 70.0%, and the differences of CR and RR between the two groups were signifcant (P < 0.05). Afer treatment, the quality of life improved signifcantly in both groups, but the combined therapy group had a higher KPS score than in the chemotherapy group (P < 0.05). The adverse events associated with the chemotherapy included gastrointestinal toxicity and myelosup-pression, and there were no signifcant differences between the two groups. The main side effects associated with radiofrequency hyperthermia included local skin ache (8.6%) and induration of subcutaneous fat (5.7%). CONCLUSION: Radiofrequency hyperthermia combined with chemotherapy is effective in treatment of malignant pericardial effusion and can signifcantly improve the quality of life of patients without increasing the toxicity of chemotherapy, and side effects could be tolerable. 中国肺癌杂志编辑部 2011-07-20 /pmc/articles/PMC6000271/ /pubmed/21762629 http://dx.doi.org/10.3779/j.issn.1009-3419.2011.07.06 Text en 版权所有©《中国肺癌杂志》编辑部2017 https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/ |
spellingShingle | 临床经验 射频透热联合化疗治疗肺癌恶性心包积液的近期疗效 |
title | 射频透热联合化疗治疗肺癌恶性心包积液的近期疗效 |
title_full | 射频透热联合化疗治疗肺癌恶性心包积液的近期疗效 |
title_fullStr | 射频透热联合化疗治疗肺癌恶性心包积液的近期疗效 |
title_full_unstemmed | 射频透热联合化疗治疗肺癌恶性心包积液的近期疗效 |
title_short | 射频透热联合化疗治疗肺癌恶性心包积液的近期疗效 |
title_sort | 射频透热联合化疗治疗肺癌恶性心包积液的近期疗效 |
topic | 临床经验 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000271/ https://www.ncbi.nlm.nih.gov/pubmed/21762629 http://dx.doi.org/10.3779/j.issn.1009-3419.2011.07.06 |
work_keys_str_mv | AT shèpíntòurèliánhéhuàliáozhìliáofèiáièxìngxīnbāojīyèdejìnqīliáoxiào AT shèpíntòurèliánhéhuàliáozhìliáofèiáièxìngxīnbāojīyèdejìnqīliáoxiào AT shèpíntòurèliánhéhuàliáozhìliáofèiáièxìngxīnbāojīyèdejìnqīliáoxiào |